# Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Source: https://onco.cc/trials/nct07100730/  
OnCo record `nct07100730` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of TLX-101-Tx + Lomustine in glioma & glioblastoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.

## Summary

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma is a phase 3 interventional study registered as NCT07100730 by Telix Pharmaceuticals (Innovations) Pty Limited, with 50 participants planned, started 2025-11-02 and due to reach its primary completion in 2027-07. Interventions recorded: TLX-101-Tx + Lomustine and TLX101-Tx.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07100730
- Phase: 3
- Setting: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07100730: https://clinicaltrials.gov/study/NCT07100730

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07100730.json